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ABSTRACT  
Objective: To develop a simple, precise, accurate, validated stability indicating reverse phase high-pressure liquid chromatography and high-
performance thin layer chromatography method for the determination of zanamivir in bulk and capsule dosage form.  
Methods: The high-pressure liquid chromatography separation was achieved on Agilent TC C18 (2) 250 x 4.6 mm, 5 μ column using mobile phase 
composition of methanol-0.02 M phosphate buffer, pH 3.5, 50:50 (v/v). Flow rate was maintained at 1 ml/min at an ambient temperature. 
Quantification was achieved with ultraviolet detection at 230 nm. The retention time obtained for zanamivir was at 3.6 min. The method employed 
thin layer chromatography aluminum plates precoated with silica gel 60F-254 as the stationary phase. The solvent system consisted of chloroform: 
methanol: acetic acid (4.5:0.5:0.3v/v) and then scanned. The system was found to give a compact spot for zanamivir (Rf value of 0.29±0.02).  
Results: In HPLC,the result obtained with the detector response was found to be linear in the concentration range of 2-12 μg/ml. In HPTLC, the 
linear regression analysis data for the calibration plots showed a good relationship with r
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=0.9999±0.0001 in the concentration range 500-3000 
ng/spot. The reliability and analytical performance of the proposed methods, including linearity, range, precision, accuracy, detection and 
quantitation limits, were statistically validated. When zanamivir was subjected to different stress conditions; the proposed methods could 
effectively separate the drug from its degradation products, and were thus considered as good stability-indicating procedures.  
Conclusion: It is concluded that this method can be applied for routine quality control of zanamivir in dosage forms as well as in bulk drug. 
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INTRODUCTION 
The chemical name of zanamivir (ZMV) is 5-(acetylamino)-4-
[(amino imino methyl)-amino]-2,6-anhydro-3,4,5-trideoxy-D-
glycero-D-galacto-non-2-enonic acid. It has a molecular formula of 
C12H20N4O7 and a molecular weight of 332.3[1, 2] as shown in fig. 1. 
The proposed mechanism of action of zanamivir is via inhibition of 
influenza virus neuraminidase with the possibility of alteration of 
virus particle aggregation and release [3, 4]. Mechanism of action 
has on viral neuraminidase catalyzes cleavages of terminal sialic 
acid residues attached to glycoprotein and glycolipids, a process 
necessary for release of virus from host cell surfaces [5]. 
 
 
Fig. 1: Chemical structure of Zanamivir 
 
A literature survey reveals there are few analytical methods such as 
ultraviolet(UV) method [6],HPLC method [7, 8] and high-throughput 
HILIC–MS/MS study[9] have been reported for estimation of ZMV, 
but there is no stability indicating method by reverse phase high-
pressure liquid chromatography (RP-HPLC), and high-performance 
thin-layer chromatography (HPTLC) was reported for ZMV. It was 
felt necessary to develop a stability indicating RP-HPLC and HPTLC 
methods for the determination of ZMV as bulk and in 
pharmaceutical dosage form. According to the stability test 
guidelines issued by ICH [10-14], in the present study, the stress 
induced stability studies were carried out for ZMV to establish its 
stability characteristics and also an analytical method develop by 
RP-HPLC and developed method was validated 
MATERIALS AND METHODS 
Materials 
A pharmaceutical grade of zanamivir kindly supplied as a gift sample 
by Cipla Ltd., Mumbai, India. All chemicals and reagents used were of 
HPLC of analytical grade and were purchased from Merck Chemical, 
India. Analytical grade sodium hydroxide, hydrochloric acid, and 
10% hydrogen peroxide were used. 
Instrumentation and chromatographic conditions 
For HPLC 
Agilent technologies 1260 LC system with a gradient pump 
connected to DAD UV detector, LC-GC AGN204PO balance was used 
for all weighing an Agilent zorbax eclipse C18 column 
(150 mm × 4.6 mm i.d., 5 μm) was maintained at 30 °C. The mobile 
phase was composed of a mixture of 
HPTLC has performed on 20 cm x 10 cm aluminum plates coated 
with silica gel aluminum plate 60F-254 (0.2 mm thickness E. Merck, 
Germany). ZMV was spotted in the form of bands of width 6 mm 
with Camagmicrolitre syringe using CamagLinomatV (Switzerland). 
A constant application rate of 150 nl/sec was employed, and space 
between two bands was 15 mm. The slit dimension was kept 6 mm x 
methanol-0.02 M phosphate 
buffer, pH 5, 50:50 (V/V). The flow rate of the mobile phase was set 
at 1 ml/min Measurements were made with 20  µl of injection 
volume. The retention time obtained for zanamivir was at 3.6 min. 
For the analysis of forced degradation samples, the photodiode 
array detector was used in scan mode with a scan range of 200–
400 nm.  
For HPTLC  
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0.45 mm micro, 20 mm/s scanning speed was employed. The mobile 
phase consisted of Chloroform: methanol: acetic acid 
(4.5:0.5:0.3v/v). The chromatogram was developed in twin trough 
glass chamber saturated with mobile phase using the linear 
ascending technique. The optimized chamber saturation time for 
mobile phase was 25 min at room temperature. The length of 
chromatogram run was approximately 80 mm. The system was 
found to give a compact spot for zanamivir (Rf value of 0.29±0.02). 
Subsequent to the development; TLC plates were dried in current of 
air with the help of an air dryer. Densitometric scanning was 
performed using Camag TLC scanner III in the absorbance mode at 
230 nm. The source of radiation utilized was deuterium lamp 
emitting a continuous UV spectrum in the range of 200-400 nm. 
Preparation of standard solution  and calibration graphs 
For HPTLC densitometry  
Accurately weighed the quantity of ZMV (10 mg) was transferred to 
10.0 ml volumetric flask. Then small amount methanol was added, 
and ultrasonicated for 5 min and diluted up to the mark with 
methanol (Concentration: 1000 μg/ml). Different volume of stock 
solution 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 μl were spotted in six replicates on 
TLC plates to obtain concentration of 500, 1000, 1500, 2000, 
2500,3000 ng/spot of zanamivir respectively 
Intra-and inter-day precisions of the methods were determined by 
performing replicate (n=3) analyses of standards and samples. This 
procedure was replicated on different days (n=3). Recovery studies 
by standard addition method were performed in view of justifying 
the accuracy of the proposed methods. Previously analyzed samples 
containing ZMV was spiked with standard ZMV, and the mixtures 
were analyzed in triplicate (n=3) by proposed methods. Precision 
was calculated from percentage relative standard deviation (RSD %) 
for repeated measurements, whereas accuracy was expressed as % 
of recovery. 
The plate was developed on previously described mobile phase. The 
peak areas were plotted against corresponding concentrations to 
obtain the calibration graphs 
For HPLC 
Stock solutions of ZMV (100 μg /ml) were prepared by transferring 
10 mg each of ZMV standard in separate 100 mL volumetric flasks, 
dissolved in 50 mL of methanol and made up to volume using the 
same. ZMV (0.2, 0.4, 0.6, 0.8, 1.0, 1.2 ml) were transferred to a series 
of 10 ml volumetric flasks and diluted up to the mark with mobile 
phase. The prepared dilutions were injected in series, peak area was 
calculated for each dilution, and concentration was plotted against 
peak area. 
Preparation of sample solution  
For HPTLC densitometry  
Twenty tablets were accurately weighed, and average weight per 
tablet was determined. Tablets were ground to fine powdered and 
weighed tablet powder equivalent to one tablet of ZMV was 
transferred to 100 ml volumetric flask. The powder was dissolved in 
30 ml methanol by intermittent shaking, and the volume was made up 
to the mark with methanol. The solution was then filtered through 
Whatman filter paper no.45. 1 µlof above solution was spotted on TLC 
plate. The analysis was repeated for six times. ZMV gave sharp and 
well-defined peaks at Rf 0.29, when scanned at 230 nm.  
For HPLC  
An accurately weighed 5 mg of ZMV was transferred into 100 ml 
volumetric flask containing 25 ml of methanol; volume was made up 
to the mark with methanol and solution was filtered using 0.45 µm 
filter (Mill filter, Milford, MA). From filtrate, 2 ml of solution was 
transferred into 10 ml volumetric flask and the volume was made up 
to mark with mobile phase to obtain the final concentration 10 
μg/ml was subjected to propose a method and the amount of ZMV 
were determined. The assay procedure was repeated for six times. 
Method validation 
The method was validated for its linearity range, accuracy, precision, 
sensitivity, and specificity. Method validation is carried out as per 
ICH guidelines. 
Precision 
Robustness and ruggedness of the method 
For HPTLC–densitometric method 
Robustness was studied in six replicate at the concentration level of 
1000 ng/spot. In this study, seven parameters (mobile phase 
composition, mobile phase volume, development distance, relative 
humidity, duration of saturation, time from spotting to 
chromatography and chromatography to spotting) were studied, 
and the effects on the results were examined. 
The ruggedness of the proposed method was studied by two 
different analysts using the same experimental and environmental 
conditions. The spots 1000 ng/band of ZMV was applied on TLC 
plates. This procedure was repeated in triplicates. 
For HPLC method 
Robustness of the method was studied by making deliberate 
variations in the chromatographic conditions and effects on the peak 
areas were recovered. Different chromatographic parameters such 
as variations in flow rate, column oven temperature, mobile phase 
composition and change in pH of mobile phase were made. It was 
performed using 10 µg/ml of ZMV and the effects on the peak areas 
were recorded. The each parameter was repeated for six times. The 
ruggedness of the method was studied by analyzing 10 µg/ml of 
ZMV by two different analyst using same operational and 
environmental conditions. 
Limit of detection and limit of quantitation 
For HPTLC–densitometric method 
The sensitivity of the proposed method was estimated in terms of 
the limit of detection (LOD) and limit of quantitation (LOQ). The LOD 
and LOQ were calculated by the use of the equation LOD = 3.3 Х 
ASD/S and LOQ = 10 Х ASD/S; where, ‘ASD’ is Average standard 
deviation of the peak height and area of the drugs, taken as a 
measure of noise, and ‘S’ is the slope of the corresponding 
calibration curve. The different volume of stock solution in the range 
1000-1500 ng/band was spotted on TLC plate. The procedure was 
repeated in triplicate.  
For HPLC method 
The sensitivity of the proposed method was estimated in terms of 
Limit of Detection (LOD) and Limit of Quantitation (LOQ). For the 
study of the sensitivity of the method lower part of the linearity, the 
curve was selected. From the stock solution, six different 
concentrations in the range of 2, 2.4, 2.8, 3.2, 3.6 and 4.0 µg/ml were 
prepared and injected into the column. Each concentration was 
injected into a column for three times, and peak area was recorded. 
The average standard deviation of peak area is 3460.69. 
The LOD was calculated using formula LOD = 3.3 ASD/S and LOQ = 
10 ASD/S, where ASD is the average standard deviation and S is the 
slope of the corresponding calibration curve line.  
Specificity 
For HPTLC–densitometric method 
To confirm the specificity of the proposed method, ZMV sample was 
spotted on TLC plate. The mobile phase designed for the method 
resolved ZMV very efficiently. The peak purity of ZMV was tested by 
correlating the spectra of ZMV extracted from tablets and standard 
ZMV at the peak start (S), peak apex (A) and at the peak end (E) 
positions. Correlation between these spectra indicated purity of ZMV 
peak {correlation r (S, M) = 0.9994, r (M, E) = 0.9998}. 
For HPLC method 
Specificity is a procedure to detect the analyte quantitatively in the 
presence of component that may be expected to be present in the 
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sample matrix, while selectivity is the procedure to detect the 
analyte qualitatively in the presence of components that may be 
expected to be present in the sample matrix.  
The method is quite selective. There was no other interfering peak 
around the retention time of ZMV; also the baseline did not show 
any significant noise. 
Recovery studies 
Recovery experiments were performed at three different levels i.e. 
80, 100 and 120 %. To the pre-analysed sample solutions, a known 
amount of standard drug solution of ZMV was over spotted at three 
different levels. 
Forced degradation studies  
A stock solution containing 10 mg for ZMV in 10 ml methanol was 
prepared. This solution was used for forced degradation to provide 
an indication of the stability-indicating property of the method.  
Acid degradation  
In HPTLC methanolic solution of the drug (10 mg) was separately 
dissolved in 10 ml of 1M HCl and these solutions were kept for 8 h at 
room temperature in dark in order to exclude the possible degradative 
effect of light. The solutions (1 ml) were taken and neutralized and then 
diluted up to 10 ml with methanol. The resultant solutions were applied 
on TLC plate in triplicate (10 μL each, i.e. 1000 ng/band). The plate was 
chromatographed as described above.  
In HPLC ZMV solution treated with 1 ml of 1 M methanolic HCl. The 
solutions were kept at room temperature for 8 hr. The solution was 
diluted with the mobile phase to reach a final concentration of 10 
μg/ml of ZMV and injected to the column. 
Base degradation  
In HPTLC methanolic solution of the drug (10 mg) was separately 
dissolved in 10 ml of 1 M NaOH solution. These solutions were kept 
for 8 h at room temperature in the dark in order to exclude the 
possible degradative effect of light. The solutions (1 ml) were taken 
and neutralized and then diluted up to 10 ml with methanol. The 
resultant solutions were applied on TLC plate in triplicate (10 μL 
each, i.e. 1000 ng/band). The plate was chromatographed as 
described above.  
In HPLC ZMV solution treated with 1 M methanolic NaOH. The 
solutions were kept at room temperature for 8 hr. The solution was 
diluted with the mobile phase to reach a final concentration of 10 
μg/ml of ZMV and injected. 
Oxidative degradation  
In HPTLC, the drug (10 mg) was dissolved in 10 ml of a methanolic 
solution of hydrogen peroxide (30% v/v) and kept for 8 h at room 
temperature in the dark, to exclude the possible degradative effect of 
light. The solution (1 ml) was then diluted to 10 ml with methanol 
and treated as described for acid and base-induced degradation. 
In HPLC, ZMV solution was treated with 1 ml of hydrogen peroxide 
10%. The solution was kept at room temperature for 8hr. Both 
solutions were kept protected from light. After the specified time 
intervals, the solutions were diluted with the mobile phase to reach 
a final concentration of 10 μg/ml of ZMV. After the previous 
treatments, the solutions were filtered with a 0.45-μm filtration disc 
prior to injection to the column 
Photochemical degradation  
The drug solution was left in sunlight for 8h. The resultant solution was 
treated as described for hydrogen peroxide-induced degradation.  
Dry heat degradation  
The powdered drug was stored for 3h. Under dry heat conditions at 
55 °C. In HPTLC, a solution of the treated powder was then prepared 
and 1000 ng/band was applied to a plate in triplicate. The plate was 
then chromatographed and treated as described above.  
In HPLC, the solution was diluted with the mobile phase to reach a 
final concentration of 10 μg/ml of ZMV. The chromatograms were 
run by injecting the sample in the column. 
RESULTS AND DISCUSSION 
Optimization of procedures 
Optimization of HPTLC–densitometric method 
The TLC procedure was optimized with a view to develop a stability 
indicating assay method. Both the pure drug and the degraded 
products were spotted on the TLC plates and run in different solvent 
systems. Initially chloroform: methanol in varying ratios was tried. 
The mobile phase chloroform: methanol 4.5:0.5 (v/v) was tried. The 
developed spot was diffused. To the above mobile phase, 0.1 ml 
acetic acid was added. Both the peaks were symmetrical in nature, 
and tailing was observed. To overcome this problem, the volume of 
acetic acid was increased to 0.3 ml, gave good resolution, sharp and 
symmetrical peak with Rf value of 0.29 for ZMV (fig. 2). Also, the 
spot for ZMV was compact and not diffused. It was observed that 
prewashing of TLC plates with methanol (followed by drying and 
activation) and pre-saturation of TLC chamber with mobile phase 
for 15 min ensure good reproducibility and peak shape of ZMV.  
 
 
Fig. 2: Densitogram of standard ZMV (Rf=0.29) 
 
Optimization of HPLC method 
Initially, a combination of methanol and water (50:50 v/v) was tried 
as a mobile phase, but a broadening of the peak was observed. Then, 
pH of the mobile phase was adjusted to 3.5; the chromatogram 
showed fronting and splitting. To overcome the problem 
combination of methanol and phosphate buffer (0.02 M) in the ratio 
of 50:50 % v/v was tried for resolution of ZMV. Good resolution and 
the symmetric peak were obtained for ZMV when the pH of the 
mobile phase was adjusted to 5.0 and column oven temperature was 
kept at 30 °C. Under these optimum chromatographic conditions, the 
retention time for ZMV was found to be 3.6±0.02 min (fig. 3), at a 
flow rate of 1.0 ml/min. The detection was carried out at 230 nm. 
Linearity 
In case of HPLC, linearity was studied by injecting six concentrations 
of standard ZMV (2, 4,6,8,10,12 μg/ml) in triplicate. In HPTLC, a 
series of dilutions and standard curves were prepared over a 
concentration range from 500-3000 ng/band of ZMV from the stock 
solution. In both methods, peak area versus concentration data was 
performed by least square linear regression analysis, whereby slope, 
intercept, and correlation coefficient were determined. 
Precision 
For HPTLC–densitometric method 
Precision was studied as intra-day and inter-day variations. An 
Intra-day variation was assessed by analyzing three different 
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concentrations 1000, 1500 and 2500 ng/band of ZMV for three 
times within a day. 
 
Fig. 3: Typical chromatogram of ZMV at 230 nm (Rt=3.6) 
 
Inter-day variation was assessed using same concentration of drug 
(mentioned above) and analyzing it for three different days, over a 
period of a week. The results are as shown in table 1. 
For HPLC method 
The precision of the method was studied by intra-day and inter-day 
variations. Intra-day variation of the method was performed by 
analyzing, the three different concentrations 4 µg/ml, 6 µg/ml and 8 
µg/ml of ZMV, for three times in the same day. Inter-day variations 
of the method were performed by analyzing the same 
concentrations for the period of the three consecutive days over a 
period of a week. The results are as shown in table 2. 
Robustness and ruggedness of the method 
For HPTLC–densitometric method 
The standard deviation of peak areas was calculated for each 
parameter. The low %R. SD indicates the robustness of the method. 
The results are as shown in table 3. 
Table 1: HPTLC intra-day and Inter-day precision studies 
Drug Conc. 
[ng/band] 
Intra-day amount found [ng] Inter-day amount found [ng] 
mean±SD [n = 3] % RSD mean±SD [ n = 3] % RSD 
 
ZMV 
1000  994.78±6.56 0.70  1002.09±17.56 1.75 
1500 1501.37±24.42 1.61 1502.63±22.97 1.52 
2500 2497.49±19.92 0.79 2491.84±34.57 1.38 
  
Table 2: HPLC intra-day and inter-day precision studies 
Drug 
 
Conc. [µg/ml] Intra-day amount found [µg/ml] Inter-day amount found [µg/ml] 
 Mean ± SD [n= 3]  % RSD  Mean ± SD [n= 3] % RSD 
ZMV 4 3.98 ± 0.03 0.79 3.97 ± 0.05 1.32 
6 5.99 ± 0.04 0.67 5.99 ± 0.03 0.62 
8 8.002 ± 0.02 0.32 8.033 ± 0.04 0.12 
 
Table 3: HPTLC robustness studies 
Parameters  SD of peak height and area [n = 6] % RSD 
Mobile phase composition    
Chloroform: methanol: acetic acid (8.0:2.0:0.3v/v). 34.21 0.56 
Chloroform: methanol: acetic acid (7:3:0.3v/v). 25.76 1.04 
Mobile phase volume (ml)   
10 27.82 0.45 
12  24.81 0.78 
Development distance (cm)   
7  36.87 0.37 
7.5  23.45 1.31 
8  41.56 1.81 
Relative humidity   
55 27.67 1.27 
65 43.56 1.63 
Duration of saturation (min)   
20  23.56 0.22 
25  42.02 0.69 
30  27.64 1.27 
Activation of prewashed TLC plates (min)   
8  19.94 0.45 
10  27.83 0.37 
12  17.93 1.76 
Time from spotting to chromatography (0, 20 and 40 min) 37.45 0.19 
Time from chromatography to scanning (0, 20 and 40 min) 23.19 0.67 
The ruggedness of the proposed method was evaluated by two different analysts. The results for ZMV were found to be 99.15% and 99.27% 
respectively. 
 
For HPLC method LOD and LOQ
The standard deviation of peak areas was calculated for each 
parameter and % R. SD was found to be less than 2%. The low % R. 
SD values as shown in table 4 indicated the robustness of the 
method. 
 
For HPTLC–densitometric method 
The LOD and LOQ were found to be 36.40 ng and 110.30 ng, 
respectively. 
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For HPLC method 
LOD and LOQ were found to be 0.15 µg and 0.46 µg, respectively.  
Recovery studies 
For HPTLC–densitometric method 
To the pre-analysed 1000 ng/band solutions, a known amount of 
standard drug solutions of ZMV was over spotted at 80 %,100 % and 
120 % levels i.e.800,1000 and 1200 ng/band. The chromatogram 
was developed and scanned. The result of % recovery was found to 
be 0.52-1.27 indicated accuracy of the method.
For HPLC 
 The results are as 
shown in table 5. 
To the preanalysed 4µg/ml solutions a known amount of standard drug 
solutions of ZMV at 80 %,100 % and 120 % levels i. e 3.2,4.0,4.8 µg/ml.% 
RSD of recovery study was found to be 0.58 to 1.13, which indicated that 
the method is accurate. The results are as shown in table 6. 
 
Parameter 
Table 4: HPLC robustness studies 
± SD of peak area % RSD 
Mobile phase composition   
a) Methanol: Buffer (51: 49 v/v) 5163.12 0.68 
b) Methanol: Buffer (49: 51 v/v) 3820.70 0.50 
 pH of mobile phase   
a) 4.1  5460.07 0.72 
b) 3.9  4481.01 0.59 
Change in flow rate   
a) 0.9 5795.81 0.77 
b) 1.0 5504.32 0.73 
Change in column temperature   
a) 25 °C 





The ruggedness of the proposed method was evaluated by two different analysts. The results for ZMV were found to be 99.78% and 99.72% respectively 
 
Table 5: Recovery studies 





±SD [ng, n = 3] 
% Recovered % 
RSD 
ZMV 1000 800 800.37±4.63 100.04 0.57 
1000 1000 1007.43±12.80 100.74 1.27 
1000 1200 1199.93±14.01 99.99 1.16 
 
Table 6: Recovery studies 
 Drug Initial amount 
[ µg/ml ] 
Amount 
added  [ µg/ml ] 
Amount recovered±SD 
[ µg/ml, n = 3] 




4.0 3.2 3.18±0.03 99.47 1.13 
4.0 4.0 3.98±0.04 99.62 1.24 
4.0 4.8 4.81±0.02 100.30 0.58 
 
System suitability 
System suitability tests were also carried out to verify 
reproducibility. The system suitability was assessed in HPTLC by 
using six replicate analysis of drugs at concentration of 1000 
ng/spot of ZMV respectively.% RSD was found to be 1.45 which was 
less than 2 indicated the method is reproducible.  In HPLC the 
parameters such as capacity factor (K), injection repeatability tailing 
factor (T), theoretical plate number (N) and resolution (Rs) for the 
principal peak and its degradation product were tested on a 10 
µg/ml sample of ZMV to assist the accuracy and precision of the 
developed HPLC system. The results are as shown in table 7. 
 
Table 7: System suitability 
System suitability parameters Proposed method 
Retention time (TR 6.64 ) 
Capacity factor (K ’ 0.76 ) 
Theoretical plate (N) 7974 
Tailing factor (T) 1.03 
  
Stability-indicating property 
For HPTLC–densitometric method 
The chromatogram of samples degraded with acid, base, hydrogen 
peroxide and light showed well-separated spots of pure ZMV as well 
as some additional peaks at different Rf values. Degradation of ZMV 
in acid, base, H2O2
For HPLC method
, dry heat and light heat are as shown in fig. 4. The 
content of ZMV remained, and percentage recovery was calculated 
and listed in table 8. 
 
The chromatogram of samples degraded with acid, base, hydrogen 
peroxide and light showed well-separated spots of pure ZMV as well as 
some additional peaks at different Retention time. ZMV was successfully 
separated from all the degradation products as confirmed by the 
resolution values calculated for each chromatogram. The number of 
degradation product with their retention time values are as shown in fig. 
5. The content of ZMV remained, and percentage recovery was 
calculated and listed in table 9. 
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Table 8: HPTLC forced degradation 
Sample exposure condition Number of degradation products 
[Rf
ZMV remained 
[1000 ng/spot]  values] 
SD Recovery [%] 
1 M HCl, 8h,RT 4(0.03,0.14,0.20,0.40) 829.9 12.98 82.99 
1 M NaOH, 8h, RT 2 (0.13,0.20) a 869.6 10.40 86.96 
10 % H2O2, 8h, RT 3 (0.16,0.22,0.27) a 853.1 7.40 85.31 
Heat, 3h, 55 °C 4 (0.16,0.22,0.27) 833.1 4.98 83.31 
Photo, 8 h No degradation 996.5 2.56 99.65 





Fig. 4: Forced degradation of Zanamivir by HPTLC 1. A-Blank HCl, B-Sample treated with HCl 2. A-Blank NaOH, B-Sample treated with NaOH 3. 
Blank H2O2, B-Sample after oxidation 4. Blank MeOH, B-Sample after exposing to heat 5. A-Blank MeOH, B-Sample after exposing to light 
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 Table 9: HPLC forced degradation studies 
 Number of degradation products [Rt values] ZMV remained [10ug/ml] SDSD Recovery [%] 
1 M HCl, 8h,RT 1 (2.7) a 8.971 9.36 89.71 
1M NaOH,8h, RT 2 (1.9,2.8) a 8.713 11.23 87.13 
30%H2O2,8h,RT 1(1.1) a 9.6.7 4.42 96.07 
Heat, 3H, 55 °C 1(1.9) 9.821 3.96 98.21 
Photo, 8 h No degradation 100.13 1.56 100.13 






Fig. 5: Forced degradation of Zanamivirby HPLC: A) 1N HCl+zanamivir; B) 1N NaOH+zanamivir; C) 10% H2O2+zanamivir; D) Dry heat 
zanamivir; E) Light heat zanamivir 
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Analysis of the marketed formulation 
Six replicate determinations were performed on the commercially 
available tablet. For ZMV recovery was found to be 100.23±0.38% 
for HPLC and for HPTLC the spots of Rf 0.29 was observed in 
chromatograms obtained from drug samples extracted from tablets 
and recovery was found to be 99.28±0.605%. There was no 
interference was observed from the excipients commonly present in 
the tablets. It may, therefore, be inferred that degradation of ZMV 
had not occurred in the marketed formulations analyzed by this 
method. The low RSD indicated that the method is suitable for 
routine estimation of ZMV in pharmaceutical dosage forms.  
CONCLUSION 
The proposed HPTLC and HPLC methods provide simple, accurate and 
reproducible quantitative analysis for determination of ZMV in tablets. 
The method was validated as per ICH guidelines. 
1. www.drugbank.ca/sys/fda_labels/DB00558. [Last accessed on 
10 Feb 2016]. 
As the method could 
effectively separate the drugs from their degradation products; 
therefore, it can be employed as a stability indicating study. 
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